IRWD — Ironwood Pharmaceuticals, Inc.
$4.83
$-0.02 (-0.41%)
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Market Cap
$799.61M
Forward P/E
3.1x
52-Week Range
N/A
IRWD Price History
Revenue vs. Net Income
$296M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$127M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
66.4%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.6x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.0%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+1.8%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
